What are the adverse drug reactions and their incidence rates associated with the FOLFIRI regimen?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

FOLFIRI Regimen Adverse Drug Reactions and Incidence Rates

The FOLFIRI regimen (irinotecan, leucovorin, and 5-fluorouracil) demonstrates a well-characterized toxicity profile with neutropenia (20-52%), diarrhea (12-61%), and gastrointestinal toxicities being the most prominent adverse reactions.

Regimen Composition

The standard FOLFIRI regimen consists of 1:

  • Irinotecan: 180 mg/m² IV over 30-90 minutes, day 1
  • Leucovorin: 400 mg/m² IV infusion matching irinotecan duration, day 1
  • 5-FU: 400 mg/m² IV bolus day 1, then 1200 mg/m²/day × 2 days (total 2400 mg/m² over 46-48 hours) continuous infusion
  • Cycle: Repeated every 2 weeks

Hematologic Adverse Reactions

Neutropenia

  • Grade 3-4 neutropenia: 20-52% 2, 3, 4
  • All-grade neutropenia: 21.6-72.7% 5, 6
  • Febrile neutropenia: Significantly increased with FOLFIRI versus doublet chemotherapy 7

Other Hematologic Toxicities

  • Leukopenia: 15.6-21% (grade 3-4) 8, 2
  • Thrombocytopenia: 18.1-31.8% (all grades) 9
  • Anemia: 19-30% (grade 2-4) 2, 3

Gastrointestinal Adverse Reactions

Diarrhea

  • Grade 3-4 diarrhea: 12-20.5% 2, 10, 8
  • All-grade diarrhea: 61.2% 5
  • Significantly increased compared to single-agent irinotecan (6.2% vs lower rates) 4

Other GI Toxicities

  • Nausea: 16.2% (all grades) 6
  • Vomiting: 11-58.2% (all grades) 10, 5
  • Anorexia: 91.4% (all grades) 5
  • Mucositis/Stomatitis: 5.2-40.9% 5, 4
  • Constipation: 47.8% 5

Non-Hematologic Adverse Reactions

Fatigue/Asthenia

  • Grade 3-4 fatigue: 10-14% 10, 3
  • All-grade asthenia: Common but specific rates vary by study

Dermatologic

  • Alopecia: 71.6% (all grades) 5
  • More prominent with irinotecan-containing regimens compared to oxaliplatin-based regimens 11, 10

Other Toxicities

  • Fever: 19.3% (all grades) 9
  • Jaundice: 18.2% (all grades) 9

Comparative Toxicity Profile

FOLFIRI demonstrates distinct toxicity patterns compared to FOLFOX 11, 10:

  • More common with FOLFIRI: Alopecia, diarrhea, febrile neutropenia
  • More common with FOLFOX: Peripheral neuropathy, less diarrhea

Treatment-Related Mortality

  • Treatment-related deaths: Rare but reported, including neutropenic sepsis and hypotension/shock 3, 8
  • Grade 5 adverse events: Approximately 1.0% in real-world settings 6

Special Considerations

UGT1A1 Polymorphisms

Patients with UGT1A1 genetic polymorphisms (Gilbert syndrome or elevated bilirubin) require dose reduction and careful monitoring due to increased risk of severe irinotecan toxicity 12.

Age-Related Toxicity

In elderly patients (≥75 years), grade 3-4 toxicities increase to 52.2-76.3% without improvement in survival outcomes, suggesting careful patient selection is critical 12, 3.

Combination with Biologics

When FOLFIRI is combined with bevacizumab, ramucirumab, or cetuximab, additional toxicities specific to the biologic agent must be anticipated 1, 2, 13.

Critical Monitoring Parameters

Monitor closely for:

  • Early-onset diarrhea (cholinergic, within 24 hours)
  • Late-onset diarrhea (days 5-10, potentially life-threatening)
  • Neutropenia nadir (typically days 7-10)
  • Dehydration secondary to GI toxicities

The toxicity profile is manageable with appropriate supportive care and dose modifications, making FOLFIRI a standard second-line option for metastatic colorectal cancer after oxaliplatin-based first-line therapy 2, 11, 14.

References

Guideline

colon cancer.

Journal of the National Comprehensive Cancer Network : JNCCN, 2011

Guideline

gastric cancer, version 2.2022, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2022

Guideline

treatment of metastatic colorectal cancer: asco guideline.

Journal of Clinical Oncology, 2023

Guideline

pancreatic adenocarcinoma, version 2.2021, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2021

Guideline

colon cancer, version 2.2021, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.